GRI Bio shares surge 38.43% after-hours after positive Phase 2a IPF trial shows FVC gains and biomarker improvements.

GRI Bio surged 38.43% in after-hours trading following the release of positive Phase 2a trial results for GRI-0621 in idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint, demonstrating a favorable safety profile with no drug-related severe adverse events, and showed biomarker improvements suggesting fibrosis resolution and alveolar basement membrane repair. Notably, 39% of treated subjects experienced increased forced vital capacity (FVC) at 12 weeks, contrasting with 80% of placebo subjects showing declines. These findings, highlighting GRI-0621’s disease-modifying potential and differentiated safety profile, underscored investor optimism about its therapeutic value in a high-unmet-need market, directly driving the sharp after-hours gain.